Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Background Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-
class new generation drugs for renal anemia. This extensive meta-analysis of randomized …

Background: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new
class of treatment for renal anemia in patients with chronic kidney disease (CKD). This meta …

Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …

What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …

Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Rationale & Objective Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are
novel, orally administered agents for anemia management in chronic kidney disease (CKD) …